Evaluation of The Effects of Different Progesterone Treatment Methods on Fetal Aneuploidy Screening Tests

Abstract

In this study, the effect of progesterone use on biomarkers due to abortion complaints in aneuploidy screenings was investigated. Two hundred seventy-six singleton pregnant patients with threatened abortion were enrolled in this retrospective study. The treatment group consisted of patients who received oral, vaginal, or intramuscular progesterone (n=137) while the control group received no progesterone (n=139). The results of the double and triple screening tests of the study groups were compared. Nuchal translucency measurements and pregnancy-associated plasma protein-A (PAPP-A), (MoM) values were significantly lower in the group that received treatment with progesterone compared to the control group (p=0.009 and p<0.001, respectively). Beta-human chorionic gonadotropin (βhCG), (MoM) and alpha-fetoprotein (MoM) were found to be statistically significantly higher in the group receiving oral progesterone treatment compared to the group receiving other types of progesterone treatment (p=0.032 and p=0.001, respectively). The PAPP-A was found to be significantly lower in the oral treatment group (p=0.001). It was also significantly lower in the hydroxyprogesterone caproate treatment group (p=0.013). In the vaginal progesterone treatment group, βhCG was significantly lower (p=0.036) than that in oral treatment group. The study showed that there is a relationship between different progesterone administration routes and fetal aneuploidy screening markers.